Novel amikacin inhaled formulation for the treatment of lower respiratory tract infections

Drugs of Today

Volumn 49, Issue 11, 2013, Pages 683-692

  Antoniu, S ^a   Azoicai, D ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Amikacin; Chronic airways infection; Cystic fibrosis; Inhaled antibiotics; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ARIKACE; BAY 41 6551; BAY 416551; CIPROFLOXACIN; LIPOSOME; SOLID LIPID NANOPARTICLE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BURKHOLDERIA CEPACIA; CITROBACTER KOSERI; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; IN VITRO STUDY; KIDNEY FUNCTION; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; MYCOPLASMA PNEUMONIAE; NEBULIZATION; NEBULIZER; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84890406974     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.11.2033101     Document Type: Article

References (49)

1. Wood, G.C. Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2011, 9(11): 993-1000.
2. Ghannam, D.E., Rodriguez, G.H., Raad, I.I., Safdar, A. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis 2009, 28(3): 253-9.
3. Lo, D., VanDevanter, D.R., Flume, P., Smyth, A. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? Respir Med 2011, 105(Suppl. 2): S9-17.
4. Ballmann, M., Smyth, A., Geller, D.E. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics. Respir Med 2011, 105(Suppl. 2): S2-8.
5. Antoniu, S.A. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa. Expert Rev Anti Infect Ther 2012, 10(12): 1439-46.
6. Geller, D.E. Aerosol antibiotics in cystic fibrosis. Respir Care 2009, 54(5): 658-70.
7. Ramsey, B.W., Pepe, M.S., Quan, J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340(1): 23-30.
8. Smaldone, G.C. Aerosolized antibiotics in mechanically ventilated patients. Respir Care 2004, 49(6): 635-9.
9. Ghaffari, S., Varshosaz, J., Saadat, A., Atyabi, F. Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles. Int J Nanomed 2011, 6: 35-43.
10. Varshosaz, J., Ghaffari, S., Khoshayand, M.R., Atyabi, F., Dehkordi, A.J., Kobarfard, F. Optimization of freeze-drying condition of amikacin solid lipid nanoparticles using D-optimal experimental design. Pharm Dev Technol 2012, 17(2): 187-94.
11. Mishra, S.K., Kattel, H.P., Acharya, J. et al. Recent trend of bacterial aetiology of lower respiratory tract infections in a tertiary care centre of Nepal. Int J Infect Microbiol 2012, 1(1): 3-8.
12. Nweze, E.I., Ezute, S., Emeka Nweze, C.C., Ogbonna, C.C., Eze, C. Bacteria etiological agents causing respiratory tract infections in children and their resistance patterns to a panel of ten antibiotics. Asian Pac J Trop Dis 2012, 2(1): 18-23.
13. Woodhead, M., Blasi, F., Ewig, S. et al. Guidelines for the management of adult lower respiratory tract infections - full version. Clin Microbiol Infect 2011, 17(Suppl. 6): E1-59.
14. Rosell, A., Monso, E., Soler, N. et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005, 165(8): 891-7.
15. Beasley, V., Joshi, P.V., Singanayagam, A., Molyneaux, P.L., Johnston, S.L., Mallia, P. Lung microbiology and exacerbations in COPD. Int J Chron Obstruct Pulmon Dis 2012, 7: 555-69.
16. Sethi, S., Murphy, T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008, 359(22): 2355-65.
17. Johnston, L. Rational use of antibiotics in respiratory tract infections. SA Pharmaceutical Journal (SAPJ) 2012, 79(4): 34-9.
18. Capelastegui, A., Espana, P.P., Bilbao, A. et al. Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis 2012, 12: 134.
19. Sherchan, J.B., Gurung, P., Bam, D.S., Sherchand, J.B. Multi-drug resistant bacterial strains in lower respiratory tract infections, antibiotic sensitivity patterns and risk factors. Nepal J Sci Technol 2012, 13(1): 157-63.
20. Farrell, P.M., Collins, J., Broderick, L.S. et al. Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis. Radiology 2009, 252(2): 534-43.
21. Loeve, M., Gerbrands, K., Hop, W.C., Rosenfeld, M., Hartmann, I.C., Tiddens, H.A. Bronchiectasis and pulmonary exacerbations in children and young adults with cystic fibrosis. Chest 2011, 140(1): 178-85.
22. Kim, H.Y., Kwon, J.W., Seo, J., Song, Y.H., Kim, B.J., Yu, J., Hong, S.J. Bronchiectasis in children: 10-year experience at a single institution. Allergy Asthma Immunol Res 2011, 3(1): 39-45.
23. Evans, D.J., Bara, A.I., Greenstone, M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev 2007(2): CD001392.
24. Sánchez-Carrillo, C., Cotarelo, M., Cercenado, E., Vicente, T., Blázquez, R., Bouza, E. Comparative in-vitro activity of sparfloxacin and eight other antimicrobial agents against clinical isolates of non-tuberculous mycobacteria. J Antimicrob Chemother 1996, 37(1): 151-4.
25. Forslöw, U., Geborek, A., Hjelte, L., Petrini, B., Heurlin, N. Early chemotherapy for non-tuberculous mycobacterial infections in patients with cystic fibrosis. Acta Paediat 2003, 92(8): 910-5.
26. Vic, P., Ategbo, S., Turck, D. et al. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Eur J Pediatr 1996, 155(11): 948-53.
27. Hirsch, E.B., Guo, B., Chang, K.-T., Cao, H., Ledesma, K.R., Singh, M., Tarn, V.H. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis 2013, 207(5): 786-93.
28. Riou, M., Carbonnelle, S., Avrain, L. et al. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of intensive care unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents 2010, 36(6): 513-22.
29. Bhat, S., Fujitani, S., Potoski, B.A., Capitano, B., Linden, P.K., Shutt, K., Paterson, D.L. Pseudomonas aeruginosa infections in the intensive care unit: can the adequacy of empirical β-lactam antibiotic therapy be improved? Int J Antimicrob Agents 2007, 30(5): 458-62.
30. Mohr, A.M., Sifri, Z.C., Horng, H.S., Sadek, R., Savetamal, A., Hauser, C.J., Livingston, D.H. Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilator-associated pneumonia. Surg Infect (Larchmt) 2007, 8(3): 349-57.
31. Lu, D., Hickey, A.J. Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS Pharm Sci Tech 2005, 6(4): E641-8.
32. Schiffelers, R., Storm, G., Bakker-Woudenberg, I. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother 2001, 48(3): 333-44.
33. Garrison, A.E., Bendele, R., Knauer, S., Wolf, J., Moon-McDermott, L., Gill, S., Colagiovanni, D.B. Evaluating the efficacy of amikacin in low-clearance unilamellar liposomes in a S. aureus local infection model. J Liposome Res 2001, 11(2-3): 243-54.
34. Fielding, R.M., Moon-McDermott, L., Lewis, R.O. Bioavailability of a small unilamellar low-clearance liposomal amikacin formulation after extravascular administration. J Drug Target 1999, 6(6): 415-26.
35. Agency, E.M. Amikacin sulfate (liposomal) for the treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis. http://www.ema.europa. eu/docs/en-GB/document-library/Orphan-designation/2009/10/WC500005716.pdf. Accessed March 24, 2013.
36. Halwani, M., Mugabe, C., Azghani, A.O., Lafrenie, R.M., Kumar, A., Omri, A. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J Antimicrob Chemother 2007, 60(4): 760-9.
37. Omri, A., Ravaoarinoro, M. Comparison of the bactericidal action of amikacin, netilmicin and tobramycin in free and liposomal formulation against Pseudomonas aeruginosa. Chemotherapy 1996, 42(3): 170-6.
38. Xiong, Y.Q., Kupferwasser, L.I., Zack, P.M., Bayer, A.S. Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiography analyses. Antimicrob Agents Chemother 1999, 43(7): 1737-42.
39. Li, Z., Zhang, Y., Wurtz, W. et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 2008, 21(3): 245-54.
40. Meers, P., Neville, M., Malinin, V. et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008, 61(4): 859-68.
41. Weers, J., Metzheiser, B., Taylor, G., Warren, S., Meers, P., Perkins, W.R. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv 2009, 22(2): 131-8.
42. Okusanya, O.O., Bhavnani, S.M., Hammel, J. et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009, 53(9): 3847-54.
43. Dupont, L.J., Clancy, J.P., Minic, P. et al. Evaluation of two phase II blinded and placebo-controlled studies of nebulized liposomal amikacin (Arikace(R)) in the treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infection Am J Respir Crit Care Med [Am Thorac Soc 2010 Int Conf (May 14-19, New Orleans) 2010] 2010, 181: A1836.
44. Niederman, M.S., Chastre, J., Corkery, K., Fink, J.B., Luyt, C.-E., García, M.S. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 2012, 38(2): 263-71.
45. Luyt, C.E., Clavel, M., Guntupalli, K. et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 2009, 13(6): R200.
46. Luyt, C.E., Eldon, M.A., Stass, H., Gribben, D., Corkery, K., Chastre, J. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure. J Aerosol Med Pulm Drug Deliv 2011, 24(4): 183-90.
47. Stass, H., Corkery, K., Gribben, D., Eldon, M.A. Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease. J Aerosol Med Pulm Drug Deliv 2011, 24(4): 191-9.
48. Antoniu, S.A., Cojocaru, I. Inhaled colistin for lower respiratory tract infections. Expert Opin Drug Deliv 2012, 9(3): 333-42.
49. Faurisson, F., Delatour, F., Jelazko, P. A simple tool for monitoring nebulized amikacin treatments based on a single urine assay. J Aerosol Med 2001, 14(1): 73-81.